174 related articles for article (PubMed ID: 16842237)
1. Chk1 inhibitors for novel cancer treatment.
Tao ZF; Lin NH
Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
[TBL] [Abstract][Full Text] [Related]
2. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
3. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
4. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
5. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
Li Q; Zhu GD
Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
[TBL] [Abstract][Full Text] [Related]
6. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
McNeely S; Beckmann R; Bence Lin AK
Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
[TBL] [Abstract][Full Text] [Related]
7. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
8. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
[TBL] [Abstract][Full Text] [Related]
9. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
[TBL] [Abstract][Full Text] [Related]
10. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
11. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
Zenvirt S; Kravchenko-Balasha N; Levitzki A
Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
[TBL] [Abstract][Full Text] [Related]
12. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
13. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
[TBL] [Abstract][Full Text] [Related]
14. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
[TBL] [Abstract][Full Text] [Related]
15. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.
Ma CX; Janetka JW; Piwnica-Worms H
Trends Mol Med; 2011 Feb; 17(2):88-96. PubMed ID: 21087899
[TBL] [Abstract][Full Text] [Related]
16. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
17. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
Bucher N; Britten CD
Br J Cancer; 2008 Feb; 98(3):523-8. PubMed ID: 18231106
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells.
Koniaras K; Cuddihy AR; Christopoulos H; Hogg A; O'Connell MJ
Oncogene; 2001 Nov; 20(51):7453-63. PubMed ID: 11709716
[TBL] [Abstract][Full Text] [Related]
19. 5‑FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53‑mutated colon cancer cells.
Akasaka T; Tsujii M; Kondo J; Hayashi Y; Ying J; Lu Y; Kato M; Yamada T; Yamamoto S; Inoue T; Tsujii Y; Maekawa A; Fujinaga T; Shiraishi E; Hiyama S; Inoue T; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Jan; 46(1):63-70. PubMed ID: 25310623
[TBL] [Abstract][Full Text] [Related]
20. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
Del Nagro CJ; Choi J; Xiao Y; Rangell L; Mohan S; Pandita A; Zha J; Jackson PK; O'Brien T
Cell Cycle; 2014; 13(2):303-14. PubMed ID: 24247149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
